Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 17/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4875856 | 0.99 | AOC3 (0.45) | AOC3CA1CA2HTT | |
| SCHEMBL14019574 | 0.91 | AOC3 (0.43) | AOC3 | |
| SCHEMBL14019580 | 0.90 | AOC3 (0.45) | AOC3CA1CA2 | |
| SCHEMBL4871264 | 0.90 | AOC3 (0.42) | AOC3CA1CA2CYP1A2POLB | |
| Hydrochloric Acid SCHEMBL4874656 | 0.90 | AOC3 (0.44) | AOC3 | |
| Hydrochloric Acid SCHEMBL4877797 | 0.89 | AOC3 (0.46) | AOC3CA1CA2 | |
| SCHEMBL14045040 | 0.89 | AOC3 (0.42) | AOC3 | |
| SCHEMBL6390525 | 0.88 | AOC3 (0.45) | AOC3 | |
| Hydrochloric Acid SCHEMBL4873779 | 0.87 | AOC3 (0.47) | AOC3 | |
| SCHEMBL14044969 | 0.87 | AOC3 (0.42) | AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442715-B2 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2008-10-28 | — | — | US | disclosed |
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | SUCAMPO AG (CH) | 2008-05-22 | — | — | US | disclosed |
| US-20070208068-A1 | Aqueous Composition Comprising Thiazole Derivative | R-TECH UENO, LTD. & ASTELLAS PHARMA INC. | 2007-09-06 | — | — | US | disclosed |
| US-20070208068-A1 | Aqueous Composition Comprising Thiazole Derivative | R-TECH UENO, LTD. & ASTELLAS PHARMA INC. | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | VCAM1, ICAM1, VAPB | AOC3 202/4885CA1 4609/4885CA2 2367/4885 |
| US-20070208068-A1 | Aqueous Composition Comprising Thiazole Derivative | SLC5A1, SLC5A2, SLC10A1 | AOC3 3576/4885CA1 884/4885CA2 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.